Comerica Bank Has $706,000 Holdings in CryoLife, Inc. (CRY)

Comerica Bank boosted its stake in CryoLife, Inc. (NYSE:CRY) by 22.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 35,148 shares of the medical equipment provider’s stock after purchasing an additional 6,443 shares during the quarter. Comerica Bank owned approximately 0.11% of CryoLife worth $706,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Louisiana State Employees Retirement System raised its holdings in shares of CryoLife by 0.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 11,100 shares of the medical equipment provider’s stock valued at $221,000 after buying an additional 100 shares in the last quarter. Creative Planning raised its holdings in shares of CryoLife by 3.0% during the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after buying an additional 200 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of CryoLife by 1.4% during the 2nd quarter. Arizona State Retirement System now owns 14,254 shares of the medical equipment provider’s stock valued at $284,000 after buying an additional 200 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its holdings in shares of CryoLife by 3.7% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 6,380 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 230 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of CryoLife by 0.9% during the 2nd quarter. Wells Fargo & Company MN now owns 31,313 shares of the medical equipment provider’s stock valued at $624,000 after buying an additional 271 shares in the last quarter. Institutional investors and hedge funds own 73.31% of the company’s stock.

In other news, VP David C. Gale sold 20,000 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $19.63, for a total value of $392,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Amy Horton sold 4,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $76,000.00. Following the completion of the transaction, the chief accounting officer now owns 98,705 shares of the company’s stock, valued at approximately $1,875,395. The disclosure for this sale can be found here. Insiders have sold 185,190 shares of company stock valued at $3,915,090 in the last quarter. 6.00% of the stock is owned by company insiders.

Shares of CryoLife, Inc. (NYSE CRY) traded down $0.65 during mid-day trading on Tuesday, hitting $19.15. The stock had a trading volume of 76,600 shares, compared to its average volume of 161,033. The company has a market cap of $662.46, a price-to-earnings ratio of 48.29 and a beta of 0.81. CryoLife, Inc. has a 12-month low of $14.02 and a 12-month high of $24.00. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29.

CryoLife (NYSE:CRY) last released its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.08. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The company had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.60 million. During the same period in the previous year, the company posted $0.13 earnings per share. The firm’s revenue was down 2.9% on a year-over-year basis. research analysts forecast that CryoLife, Inc. will post 0.28 EPS for the current fiscal year.

A number of equities analysts recently weighed in on CRY shares. Zacks Investment Research raised CryoLife from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Canaccord Genuity reaffirmed a “buy” rating and issued a $25.00 price target on shares of CryoLife in a research note on Monday, October 9th. Lake Street Capital lifted their price target on CryoLife to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, October 11th. TheStreet cut CryoLife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Finally, Northland Securities reiterated a “buy” rating and issued a $23.50 price objective on shares of CryoLife in a research report on Monday, November 13th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $23.63.

TRADEMARK VIOLATION WARNING: This story was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2017/12/05/comerica-bank-has-706000-holdings-in-cryolife-inc-cry.html.

CryoLife Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit